CLINICAL PROFILES AND TREATMENT OUTCOMES IN PATIENTS WITH HEMOLYTIC VS. MEGALOBLASTIC ANEMIA

Abstract

Background: Hemolytic Anemia (HA) is a group of disorders characterized by premature destruction of red blood cells (RBCs) leading to anemia. Accurate diagnosis and appropriate management are crucial for optimizing patient outcomes.
Diagnosis of Hemolytic Anemia: Diagnosis of HA involves a comprehensive evaluation including clinical history, physical examination, laboratory tests, and imaging studies. Key diagnostic markers include elevated reticulocyte count, increased serum lactate dehydrogenase (LDH) levels, unconjugated hyperbilirubinemia, and characteristic changes in mean corpuscular volume (MCV). Differentiation from other causes of anemia, such as nutritional deficiencies or bone marrow disorders, is essential.
Results and Analysis: Our analysis highlights significant differences in laboratory parameters and treatment approaches between HA and other forms of anemia. Reticulocyte count and LDH levels were consistently elevated in HA, while MCV alterations were observed in specific subtypes. Treatment modalities, including corticosteroids, splenectomy, and blood transfusion, demonstrated variable effectiveness depending on the underlying etiology of HA.
Conclusion: In conclusion, accurate diagnosis and tailored management strategies are essential for improving outcomes in patients with HA. Understanding the diagnostic criteria and treatment options is critical for healthcare providers to provide optimal care and enhance patient quality of life.